The goal of the Innovative Medicines Initiative 2 (IMI 2) programme is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI’s first phase. As before, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry.
The IMI 2 programme will provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments. Cost savings will ease the burden on public healthcare systems and greater coordination across industry sectors will result in more reliable and faster clinical trials, and better regulation. IMI 2 research and innovation efforts will also open new commercial possibilities based on new services and products. The research, industry and societal sectors involved in IMI 2 programmes will benefit from the cooperation and knowledge sharing which take place in these projects.

In particular, IMI 2 aims to deliver:

  • a 30% better success rate in clinical trials of priority medicines identified by the WHO;
  • clinical proof of concept in immunological, respiratory, neurological and neurodegenerative diseases in just five years;
  • new and approved diagnostic markers for four of these diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease.

More information: